HLB says bile duct cancer drug lirafugratinib enters full review for European approval
HLB's novel cholangiocarcinoma treatment, lirafugratinib, has entered full review for authorization in Europe following its approval by the U.S. Food and Drug Administration (FDA).HLB announced on the 7th that its U.S. subsidiary, Elevar Therapeutics, received notification from the European Medicines Agency (EMA) that the review of its Marketing Authorisatio..